痴呆诊断对老年人潜在不适当用药模式的影响
基于美国国家阿尔茨海默病协调中心数据的纵向研究,将2005-2015年新诊断痴呆的65岁以上患者(n=2,418)与对照按年龄、性别1:1匹配。痴呆患者诊断前1年药物数比诊断年低8%,诊断后1年比诊断年高11%;潜在不适当用药(PIM)暴露在诊断前1年低17%,诊断后1年高17%。对照组逐年药物数增加约6%,PIM暴露逐年增加11%。
要点
- 痴呆患者诊断前1年用药数和PIM暴露低于诊断年,诊断后1年则高于诊断年。
- 对照组药物数和PIM暴露均逐年增加,痴呆组每年PIM暴露几率均低于对照。
- 两组抗胆碱能药物暴露无差异,痴呆组PIM使用持续增加需干预。
核心结论
- 痴呆患者和对照组的药物数量及PIM使用均逐年增加,痴呆患者诊断后PIM暴露较诊断年升高。
研究设计与样本
- 纵向研究,使用美国国家阿尔茨海默病协调中心数据,纳入2005-2015年新诊断痴呆的65岁以上成人(n=2,418),按年份、年龄、性别1:1匹配对照,采用广义估计方程模型并校正15项参与者特征。
主要发现
- 痴呆患者诊断前1年报告的药物数量比诊断年低8%(p < .0001),诊断后1年比诊断年高11%(p < .0001)。
- 痴呆患者诊断前1年PIM暴露几率比诊断年低17%(p < .0001),诊断后1年比诊断年高17%(p = .006)。
- 对照组连续年份间药物数量增加约6%(每次比较p < .0001),PIM暴露几率增加11%(p = .006和p = .047)。
- 每个年度随访中,痴呆患者PIM暴露几率均低于对照(诊断前p < .0001,诊断时p = .0007,诊断后p = .03)。
- 两组抗胆碱能药物暴露无差异。
关键数值与推荐
- PIM评估采用2015年Beers标准。
临床怎么用
- 对痴呆老年患者应关注诊断前后用药数量的变化,尤其在诊断后1年加强PIM审查与干预以减少不适当处方。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Use of potentially inappropriate medications (PIM) among people with dementia is common. We assessed the patterns of medication use from 1-year before dementia diagnosis, to 1-year after dementia diagnosis, compared with patterns of medication use in people without dementia. METHODS: We conducted longitudinal study using the National Alzheimer's Coordinating Center data. Adults aged 65 years and older newly diagnosed with dementia (n = 2,418) during 2005-2015 were year, age, and sex matched 1:1 with controls. Generalized estimating equation models weighted for missingness and adjusted for 15 participant characteristics were fit. RESULTS: Among participants with dementia, number of medications reported 1-year prediagnosis was 8% lower than at diagnosis year (p < .0001) and 11% higher 1-year postdiagnosis compared with year of diagnosis (p < .0001). Among participants with dementia, the odds of PIM exposure, assessed using the 2015 Beers Criteria, was 17% lower 1-year prediagnosis (p < .0001) and 17% higher 1-year postdiagnosis (p = .006) compared with year of diagnosis. Among controls, there were approximately 6% more medications reported between consecutive years (p < .0001 each comparison) and the odds of PIM exposure increased 11% between consecutive years (p = .006 and p = .047). At each annual follow-up, participants with dementia had lower odds of PIM exposure than their controls (prediagnosis p < .0001, at diagnosis p = .0007, postdiagnosis p = .03, respectively). There were no differences in exposure to anticholinergic medications. CONCLUSIONS: Number of medications and PIM use increased annually for participants with and without dementia. Persistent challenge of increasing PIM use in this group of older adults is of major concern and warrants interventions to minimize such prescribing.
引用
- Gnjidic D, Agogo GO, Ramsey CM, et al. The Impact of Dementia Diagnosis on Patterns of Potentially Inappropriate Medication Use Among Older Adults. J Gerontol A Biol Sci Med Sci. 2018. PMID: 29684111. doi:10.1093/gerona/gly078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。